Banaba Inositol Composition for PCOS Insulin Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for polycystic ovary syndrome (PCOS) often come with significant side effects and are not effective for long-term management, particularly hormonal therapies which can lead to undesirable effects such as hot flushes, visual disturbances, and impaired pancreatic function.
Innovation Solution
A composition combining Banaba (Lagerstroemia speciosa) extract, inositol, and Ipomoea Batatas, with optional lignans, is administered to enhance insulin sensitivity, reduce insulin resistance, and alleviate PCOS symptoms without inducing hormonal therapy side effects, offering a synergistic effect for improved ovulatory function and metabolic regulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormonal therapy (oestroprogestinic therapy) is administered to treat PCOS, then menstrual cycle regularity is improved and hyperandrogenism is reduced, but side effects occur such as hot flushes, visual disturbances, and impaired pancreatic function
Solution Approach 1:
The patent introduces an intermediary substance (inositol) that mediates the treatment of PCOS by improving insulin sensitivity and reducing hyperandrogenism through a different pathway than hormonal therapy. Inositol acts as a mediator that addresses the root metabolic dysfunction rather than merely suppressing symptoms, thereby avoiding the side effects associated with direct hormonal intervention while still achieving menstrual regularity and reduced androgen levels
Solution Approach 2:
The patent replaces the mechanical/hormonal system (exogenous hormones) with a metabolic intervention (inositol supplementation) that works through insulin sensitivity improvement. This substitution changes the mechanism of action from direct hormonal replacement to metabolic regulation, thereby treating PCOS through its metabolic root cause rather than through hormonal suppression, which eliminates the side effects of hot flushes, visual disturbances, and pancreatic impairment
2Productivity
If clomiphene is administered to induce ovulation, then ovulation occurs, but undesirable effects occur such as hot flushes, blood component changes, and visual disturbances
Solution Approach 1:
The patent uses inositol as an intermediary that indirectly promotes ovulation by improving insulin sensitivity and reducing hyperandrogenism. Rather than directly stimulating ovulation like clomiphene, inositol mediates the process by correcting the underlying metabolic dysfunction, thereby achieving ovulation induction without the undesirable effects of hot flushes, blood component changes, and visual disturbances
Solution Approach 2:
The patent converts the harmful effect of insulin resistance and hyperinsulinemia into a beneficial outcome by using inositol to improve insulin sensitivity. The metabolic dysfunction that originally caused anovulation is transformed into a therapeutic opportunity, where correcting insulin resistance leads to reduced androgen levels and restored ovulatory function without the side effects of clomiphene
3Productivity
If FSH is administered to induce ovulation, then follicular maturation is improved, but superovulation and ovarian hyperstimulation syndrome occur
Solution Approach 1:
The patent uses inositol as an intermediary that gently promotes follicular maturation through metabolic regulation rather than direct hormonal stimulation. Inositol improves insulin sensitivity, which indirectly supports follicular development by reducing insulin resistance and associated androgen excess, thereby achieving follicular maturation without the excessive stimulation and hyperstimulation syndrome caused by high-dose FSH
Solution Approach 2:
The patent applies partial action by using inositol supplementation at physiological doses rather than excessive hormonal stimulation. This partial intervention is sufficient to correct the metabolic dysfunction and support natural follicular maturation without overwhelming the ovarian system, thereby avoiding superovulation and ovarian hyperstimulation syndrome while still improving follicular development
4Reliability
If oral hypoglycaemic agents are administered to reduce hyperinsulinaemia, then metabolic changes are improved, but pancreatic function is impaired with long-term use
Solution Approach 1:
The patent uses inositol, a naturally occurring substance with no known toxicity and no risk of long-term pancreatic impairment. Unlike oral hypoglycaemic agents that require careful monitoring and have limited long-term safety profiles, inositol can be used indefinitely without accumulating toxicity or causing pancreatic dysfunction, making it a safer long-term treatment option for PCOS
Solution Approach 2:
The patent changes the parameter of treatment safety by using inositol, which has a fundamentally different safety profile from oral hypoglycaemic agents. Inositol is a naturally occurring compound with no known adverse effects even with long-term use, whereas oral hypoglycaemic agents carry risks of pancreatic impairment and other side effects. This parameter change enables long-term treatment without the safety concerns associated with conventional hypoglycaemic therapy
Data Source
AI summary
The present invention in one aspect concerns a composition for the prevention and/or treatment of polycystic ovary syndrome and its related symptoms, comprising a combination of Banaba extract (Lagerstroemia speciosa L.), inositol in one of its chiral or salt forms, lpomoea Batatas and a physiologically acceptable carrier. The composition can further contain lignans and be a herbal product, a food supplement, a dietetic and/or a nutritional product.